首站-论文投稿智能助手
典型文献
Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
文献摘要:
Dear Editor, Most recently,a new SARS-CoV-2 variant of concern(VOC),Omicron(B.1.1.529),was first reported to the World Health Organization(WHO)from South Africa and then quickly spread to many countries,1,2 posing a serious threat to current vaccine prevention and antibody therapeutic strategies.Several studies have reported that the Omicron variant successfully escapes from neutralizing antibodies elicited by COVID-19 vaccines or from COVID-19 convalescent patients.3,4 Therefore,the development of potent anti-Omicron agents is urgently needed.
文献关键词:
作者姓名:
Shuai Xia;Jasper Fuk-Woo Chan;Lijue Wang;Fanke Jiao;Kenn Ka-Heng Chik;Hin Chu;Qiaoshuai Lan;Wei Xu;Qian Wang;Chao Wang;Kwok-Yung Yuenuai;Lu Lu;Shibo Jiang
作者机构:
Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences,Shanghai Frontiers Science Center of Pathogenic Microbes and Infection,Shanghai Institute of Infectious Disease and Biosecurity,Fudan University,Shanghai,China;State Key Laboratory of Emerging Infectious Diseases,Carol Yu Centre for Infection,Department of Microbiology,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;Department of Clinical Microbiology and Infection Control,The University of Hong Kong-Shenzhen Hospital,Shenzhen,Guangdong,China;Centre for Virology,Vaccinology and Therapeutics,Hong Kong Science and Technology Park,Hong Kong,China;State Key Laboratory of Toxicology and Medical Countermeasures,Beijing Institute of Pharmacoloay and Toxicoloay,Beijing,China
引用格式:
[1]Shuai Xia;Jasper Fuk-Woo Chan;Lijue Wang;Fanke Jiao;Kenn Ka-Heng Chik;Hin Chu;Qiaoshuai Lan;Wei Xu;Qian Wang;Chao Wang;Kwok-Yung Yuenuai;Lu Lu;Shibo Jiang-.Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant)[J].细胞研究(英文版),2022(04):404-406
A类:
B类:
Peptide,pan,CoV,fusion,inhibitors,maintain,high,potency,against,SARS,Omicron,variant,Dear,Editor, Most,recently,new,concern,VOC,was,first,reported,World,Health,Organization,WHO,from,South,Africa,then,quickly,spread,many,countries,posing,serious,threat,current,prevention,antibody,therapeutic,strategies,Several,studies,have,that,successfully,escapes,neutralizing,antibodies,elicited,by,vaccines,convalescent,patients,Therefore,development,potent,agents,is,urgently,needed
AB值:
0.774685
相似文献
Common mtDNA variations at C5178a and A249d/T6392C/G10310A decrease the risk of severe COVID?19 in a Han Chinese population from Central China
Yi Wu;Xian‑Hui Wang;Xi‑Hua Li;Li‑Yuan Song;Shi‑Long Yu;Zhi‑Cheng Fang;Yu‑Quan Liu;Le‑Yong Yuan;Chun‑Yan Peng;Shen‑Yi Zhang;Wang Cheng;Hong‑Chao Ma;Li‑Feng Wang;Jun‑Ming Tang;Yun‑Fu Wang;Fu‑Yun Ji-Department of Medical Biology,School of Basic Medical Science,Hubei University of Medicine,Shiyan 442000,Hubei,China;Institute of Biomedical Research,Hubei University of Medicine,Shiyan 442000,Hubei,China;Institute of Human Respiratory Disease,Xinqiao Hospital,The Army Medical University(Third Military Medical University),400037 Chongqing,China;Department of Emergency Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Geriatric Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Immunology,School of Basic Medical Sciences,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Laboratory Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China;Hubei Key Laboratory of Embryonic Stem Cell Research,School of Basic Medical Science,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Neurology,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China
An ultrapotent pan-β-coronavirus lineage B(β-CoV-B)neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
Zezhong Liu;Wei Xu;Zhenguo Chen;Wangjun Fu;Wuqiang Zhan;Yidan Gao;Jie Zhou;Yunjiao Zhou;Jianbo Wu;Qian Wang;Xiang Zhang;Aihua Hao;Wei Wu;Qianqian Zhang;Yarning Li;Kaiyue Fan;Ruihong Chen;Qiaochu Jiang;Christian T.Mayer;Till Schoofs;Youhua Xie;Shibo Jiang;Yumei Wen;Zhenghong Yuan;Kang Wang;Lu Lu;Lei Sun;Qiao Wang-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences;Shanghai Institute of Infectious Disease and Biosecurity;the Fifth People's Hospital of Shanghai;Shanghai Key Laboratory of Medical Epigenetics,International Co-laboratory of Medical Epigenetics and Metabolism(Ministry of Science and Technology);Institutes of Biomedical Sciences;Biosafety Level 3 Laboratory,Shanghai Medical College,Fudan University,Shanghai 200032,China;CAS Key Laboratory of Infection and Immunity,National Laboratory of Macromolecules,Institute of Biophysics,Chinese Academy of Sciences,Beijing 100101,China;Experimental Immunology Branch,Center for Cancer Research,National Cancer Institute,National Institutes of Health,Bethesda,MD 20892,USA;GSK Vaccines,1300 Wavre,Belgium
Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants
Jia Lu;Qiangling Yin;Rongjuan Pei;Qiu Zhang;Yuanyuan Qu;Yongbing Pan;Lina Sun;Ding Gao;Cuiqin Liang;Jingwen Yang;Wei Wu;Jiandong Li;Zongqiang Cui;Zejun Wang;Xinguo Li;Dexin Li;Shiwen Wang;Kai Duan;Wuxiang Guan;Mifang Lian;Xiaoming Yang-National Engineering Technology Research Center for Combined Vaccines,Wuhan Institute of Biological Products Co.Ltd.,Wuhan,430070,China;State Key Laboratory for Molecular Virology and Genetic Engineering National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing,102206,China;Center for Emerging Infectious Diseases,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan,430071,China;CDC-WIV Joint Research Center for Emerging Diseases and Biosafety,Wuhan,430071,China;Institution of Infectious Diseases,Shenzhen Bay Laboratory,Shenzhen,518107,China
Characteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates
Xiao-Li Feng;Dandan Yu;Mi Zhang;Xiaohong Li;Qing-Cui Zou;Wentai Ma;Jian-Bao Han;Ling Xu;Cuixian Yang;Wang Qu;Zhong-Hua Deng;Junyi Long;Yanghaopeng Long;Mingkun Li;Yong-Gang Yao;Xing-Qi Dong;Jianxiong Zeng;Ming-Hua Li-Kunming National High-level Biosafety Research Center for Non-Human Primates,Center for Biosafety Mega-Science,Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming,650107,China;Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences,and KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases,Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming,650201,China;National Resource Center for Non-Human Primates,National Research Facility for Phenotypic&Genetic Analysis of Model Animals(Primate Facility),Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming 650107,China;Department of Infectious Diseases,Yunnan Provincial Infectious Diseases Hospital,Kunming,650301,China;Key Laboratory of Genomic and Precision Medicine,Beijing Institute of Genomics,Chinese Academy of Sciences,and China National Center for Bioinformation,Beijing,100101,China;University of Chinese Academy of Sciences,Beijing,100049,China;Center for Excellence in Animal Evolution and Genetics,Chinese Academy of Sciences,Kunming,650201,China;Kunming College of Life Science,University of Chinese Academy of Sciences,Kunming 650204,China;Yunnan Key Laboratory of Biodiversity Information,Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming,650201,China
Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum
Yuqi Zhu;Xinyi Yang;Jingna Xun;Jun Liu;Qing Wen;Yixiao Lin;Xiaoting Shen;Jun Chen;Songhua Yuan;Xiaying Zhao;Jing Wang;Hanyu Pan;Jinlong Yang;Zhiming Liang;Yue Liang;Qinru Lin;Huitong Liang;Min Li;Jianping Liu;Yinzhong Shen;Xiaoyan Zhang;Pengfei Wang;Daru Lu;Chunhua Yin;Jianqing Xu;Shibo Jiang;Hongzhou Lu;Huanzhang Zhu-State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology,Ministry of Education,Institute of Genetics,School of Life Sciences,Fudan University,Shanghai,200438,China;Scientific Research Center,Shanghai Public Health Clinical Center,Fudan University,Shanghai,201508,China;Fubio(Suzhou)Biomedical Technology Co.,Ltd,Suzou,215300,China;Department of Infectious Diseases and Immunology,Shanghai Public Health Clinical Center,Fudan University,Shanghai,201508,China;Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences,Fudan University,Shanghai,200032,China;Department of Infectious Diseases and Nursing Research Institution,National Clinical Research Center for Infectious Diseases,The Third People's Hospital of Shenzhen,Shenzhen,518112,China
Clinical practice of rapid antigen tests for SARS-CoV-2 Omicron variant:A single-center study in China
Mengyuan Chen;Jiaqin Xu;Lingjun Ying;Miaoguo Cai;Tao-Hsin Tung;Kai Zhou;Yufen Zheng;Xiaojie Bi;Jing Wang;Xi Tu;Bo Shen;Dongqing Lv-Department of Laboratory Medicine,Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University,Taizhou,317000,China;Hepatology and Infectious Diseases Center,Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University,Taizhou,317000,China;Department of Radiation Oncology,Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University,Taizhou,317000,China;Evidence-based Medicine Center,Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University,Taizhou,317000,China;Department of Respiratory and Critical Diseases,Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University,Taizhou,317000,China
A pair of SARS-CoV-2 nucleocapsid protein monoclonal antibodies shows high specificity and sensitivity for diagnosis
An-Kai Zhu;Sa-Sa Li;Shu-Pei Yu;Zhao-Yong Zhang;Huan Li;Jing-Feng Li;Shan-Shan Gao;Heng Chen;Jincun Zhao;Run Shi;Mingjian Lu;Chaoyang Li-Affiliated Cancer Hospital and Institute of Guangzhou Medical University,State Key Laboratory of Respiratory Disease,Key Laboratory for Cell Homeostasis and Cancer Research of Guangdong High Education Institute,Guangzhou,510095,China;State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,510182,China;Department of Interventional Radiology,Affiliated Cancer Hospital and Institute of Guangzhou Medical University,Guangzhou,510095,China
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。